Fridays Pricing represents a subscription-based model for GLP-1 access, but understanding how treatment costs are structured requires evaluating compounded versus branded options, pharmacy credentials, and individual clinical factors that influence eligibility and dosing.

Fridays is a telehealth GLP-1 program dispensing compounded semaglutide and tirzepatide through licensed 503A pharmacies. This independent PlexusDx review compares its advertised month-to-month pricing, pharmacy standards, and support with the PlexusDx approach.

Ro and Fridays are telehealth platforms offering GLP-1 prescriptions through remote medical evaluation, but they differ in drug selection, pricing models, and clinical assessment depth.

Mochi Health and Fridays both deliver GLP-1 therapy by telehealth, so the real comparison is the experience: onboarding, dose titration, and follow-up. This independent PlexusDx review walks through each program and the inherited pathway genetics neither service is built to measure.

Hims is a broad multi-category telehealth brand; Fridays is a focused weight program. This independent review compares how each structures its GLP-1 offer, what the pricing looks like, and the upstream genetic layer that neither platform maps before a prescription is written.

Zepbound is branded tirzepatide, so a Fridays search is really a sourcing question. This independent editorial review separates the brand name from the molecule, covers compounded-versus-branded routing and pricing, and the FTO, MC4R, and TCF7L2 pathway context behind it.